Anchal Ghai

441 total citations · 1 hit paper
17 papers, 289 citations indexed

About

Anchal Ghai is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Hematology. According to data from OpenAlex, Anchal Ghai has authored 17 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Oncology and 6 papers in Hematology. Recurrent topics in Anchal Ghai's work include Radiopharmaceutical Chemistry and Applications (9 papers), Peptidase Inhibition and Analysis (8 papers) and Multiple Myeloma Research and Treatments (6 papers). Anchal Ghai is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (9 papers), Peptidase Inhibition and Analysis (8 papers) and Multiple Myeloma Research and Treatments (6 papers). Anchal Ghai collaborates with scholars based in United States, India and Thailand. Anchal Ghai's co-authors include Samuel Achilefu, Monica Shokeen, Shili Li, Christopher Egbulefu, Guosheng Liang, Jin Ye, Ruihui Zhang, Yaqin Deng, Baljinder Singh and John F. DiPersio and has published in prestigious journals such as ACS Nano, Molecular Cell and Scientific Reports.

In The Last Decade

Anchal Ghai

15 papers receiving 286 citations

Hit Papers

Identification of hyperoxidized PRDX3 as a ferroptosis ma... 2023 2026 2024 2025 2023 25 50 75

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anchal Ghai United States 9 106 104 79 75 66 17 289
Stephen Eppler United States 8 188 1.8× 44 0.4× 99 1.3× 143 1.9× 29 0.4× 9 404
Zuoxing Niu China 9 163 1.5× 103 1.0× 55 0.7× 152 2.0× 112 1.7× 40 376
Carina Hage Switzerland 6 171 1.6× 71 0.7× 22 0.3× 135 1.8× 62 0.9× 7 342
Kimihiro Ito Japan 12 185 1.7× 142 1.4× 60 0.8× 156 2.1× 35 0.5× 26 482
Yasuhiro Arakawa Japan 11 150 1.4× 86 0.8× 26 0.3× 159 2.1× 94 1.4× 37 380
Yiming Zhao China 10 122 1.2× 72 0.7× 14 0.2× 131 1.7× 64 1.0× 19 293
Stephan Macher-Göppinger Germany 8 146 1.4× 56 0.5× 13 0.2× 63 0.8× 37 0.6× 16 311
Eric Raymond France 4 152 1.4× 132 1.3× 41 0.5× 229 3.1× 29 0.4× 8 387
Xueyan Wang China 5 81 0.8× 53 0.5× 48 0.6× 240 3.2× 24 0.4× 7 391

Countries citing papers authored by Anchal Ghai

Since Specialization
Citations

This map shows the geographic impact of Anchal Ghai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anchal Ghai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anchal Ghai more than expected).

Fields of papers citing papers by Anchal Ghai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anchal Ghai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anchal Ghai. The network helps show where Anchal Ghai may publish in the future.

Co-authorship network of co-authors of Anchal Ghai

This figure shows the co-authorship network connecting the top 25 collaborators of Anchal Ghai. A scholar is included among the top collaborators of Anchal Ghai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anchal Ghai. Anchal Ghai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ghai, Anchal, Christopher Egbulefu, Kvar C. L. Black, et al.. (2025). Chemo-RaST with bortezomib inhibits multiple myeloma relapse. Theranostics. 15(18). 9911–9921.
2.
Zheleznyak, Alexander, Rui Tang, Brad Manion, et al.. (2024). Development of New CD38 Targeted Peptides for Cancer Imaging. Molecular Imaging and Biology. 26(4). 738–752. 6 indexed citations
3.
Laforest, Richard, Anchal Ghai, Tyler J. Fraum, et al.. (2024). #27. First-in-human evaluation of safety and dosimetry of 64Cu-LLP2A for PET imaging. Journal of bone oncology. 45. 100565–100565.
4.
Ghai, Anchal, Yaqin Deng, Shili Li, et al.. (2023). Identification of hyperoxidized PRDX3 as a ferroptosis marker reveals ferroptotic damage in chronic liver diseases. Molecular Cell. 83(21). 3931–3939.e5. 92 indexed citations breakdown →
5.
Laforest, Richard, Anchal Ghai, Tyler J. Fraum, et al.. (2022). First-in-Humans Evaluation of Safety and Dosimetry of64Cu-LLP2A for PET Imaging. Journal of Nuclear Medicine. 64(2). 320–328. 16 indexed citations
6.
Chanswangphuwana, Chantiya, Nicholas S. Cho, Francesca Fontana, et al.. (2022). Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. Scientific Reports. 12(1). 30–30. 13 indexed citations
7.
Ghai, Anchal, Francesca Fontana, John F. DiPersio, et al.. (2021). In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET. EJNMMI Research. 11(1). 97–97. 7 indexed citations
8.
Ghai, Anchal, Alexander Zheleznyak, Julie O’Neal, et al.. (2020). Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging. 48(5). 1302–1311. 9 indexed citations
9.
Tang, Rui, Alexander Zheleznyak, Anchal Ghai, et al.. (2020). Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma. ACS Nano. 14(4). 4255–4264. 32 indexed citations
10.
Singh, Baljinder, Ashwani Koul, Anil K. Mishra, et al.. (2019). Radiosynthesis and pre-clinical evaluation of [ Ga] labeled antimicrobial peptide fragment GF-17 as a potential infection imaging PET radiotracer. Applied Radiation and Isotopes. 149. 9–21. 8 indexed citations
11.
Ghai, Anchal, Baljinder Singh, Mengshi Li, et al.. (2018). Optimizing the radiosynthesis of [68Ga]DOTA-MLN6907 peptide containing three disulfide cyclization bonds – a GCC specific chelate for clinical radiopharmaceuticals. Applied Radiation and Isotopes. 140. 333–341. 2 indexed citations
12.
Ghai, Anchal, Nicholas S. Cho, Chantiya Chanswangphuwana, et al.. (2017). Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. Journal of Nuclear Medicine. 59(2). 216–222. 47 indexed citations
13.
Kumar, Pardeep, et al.. (2016). Radiosynthesis of [18F]-fluorobenzoate-doxorubicin Using Acylation Approach. Current Radiopharmaceuticals. 9(3). 215–221. 2 indexed citations
14.
Kumar, Pardeep, Baljinder Singh, Anchal Ghai, et al.. (2015). Preclinical evaluation of 99mTc labeled gefitinib as a potential scintigraphic probe for the detection of tumors expressing epidermal growth factor receptors. Applied Radiation and Isotopes. 99. 41–45. 3 indexed citations
15.
Kumar, Pardeep, Baljinder Singh, Anchal Ghai, et al.. (2015). Development of a single vial kit formulation of [99mTc]‐labeled doxorubicin for tumor imaging and treatment response assessment‐preclinical evaluation and preliminary human results. Journal of Labelled Compounds and Radiopharmaceuticals. 58(6). 242–249. 11 indexed citations
16.
Singh, Virendra, Ajay Singh, Baljinder Singh, et al.. (2013). Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study. The American Journal of Gastroenterology. 108(4). 560–567. 29 indexed citations
17.
Kumar, Pardeep, Baljinder Singh, Sarika Sharma, et al.. (2012). Preclinical Evaluation of [99m]Tc-Labeled Doxorubicin as a Potential Scintigraphic Probe for Tumor Imaging. Cancer Biotherapy and Radiopharmaceuticals. 27(3). 221–225. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026